Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients

• Status: Completed
• Trial end date: 2019-10-08
• Target enrollment: 0
• Participant gender: All

Summary

Researchers are trying to learn more about using sublingual (absorption under the tongue) tacrolimus in blood and marrow transplant patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Tacrolimus

Criteria

Inclusion Criteria:

• Individuals will be identified from within the adult allogeneic BMT program at Mayo Clinic in Rochester, Minnesota

• Adults prescribed tacrolimus for treatment or prevention of Graft Versus Host Disease (GVHD)

Exclusion Criteria:

• Vulnerable populations

• Patients with contraindications to tacrolimus, inclusive of hypersensitivity, history of posterior reversible encephalopathy syndrome or calcineurin-inhibitor induced thrombotic microangiopathy

• Lacking the capacity to consent in English and declining to participate in research